An endemic coronavirus appears to be the premise that leading Indian firm Cipla Limited is factoring into its business, at least for now, and that in turn could mean a sustained revenue stream for its COVID-19 therapies in the immediate future.
Cipla saw strong growth of its prescription business in India in the second quarter of fiscal 2021, driven by continued...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
